Takeda still on the hook for €398M tax linked to distant AbbVie-Shire breakup fee

Takeda has largely washed its hands of the debt it incurred in its pricey Shire buyout, but a tax break fee tethered to that company's futile merger with AbbVie continues to haunt the Japanese drugmaker.